Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06067230 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

A Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.

Active
Registry status
Phase 3
Development phase
1,153
Enrollment target
20
Study locations

NCT06067230 is a Phase 3 study of Respiratory Syncytial Virus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 1,153 participants, above the 232-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (397% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06067230, a Phase 3 study of Respiratory Syncytial Virus, is active but no longer recruiting, sponsored by ModernaTX.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,153 participants
Enrollment target
20
Study locations

Study Summary

The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).

Conditions Studied

Respiratory Syncytial Virus

Interventions

  • BIOLOGICAL mRNA-1345

Study Locations (20)

Arizona

  • Lenzmeier Family Medicine - CCT - PPDS - Glendale
  • Foothills Research Center - CCT - PPDS - Phoenix
  • Fiel Family & Sports Medicine - PC - CCT - PPDS - Tempe

Florida

  • Excel Medical Clinical Trials DBA Flourish - Boca Raton
  • Indago Research and Health Center - Hialeah
  • CenExel RCA - Hollywood - Hollywood

California

  • David Geffen School of Medicine at UCLA - Los Angeles
  • Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS - San Diego

Illinois

  • University of Chicago - Chicago
  • AES - DRS - Optimal Research Illinois - Peoria - Peoria

Michigan

  • Henry Ford Hospital - Detroit
  • DM Clinical Research - Southfield - ERN - PPDS - Southfield

Arkansas

  • Baptist Health Center for Clinical Research - Little Rock

Colorado

  • Critical Care, Pulmonary and Sleep Associates / CCT Research - Lakewood

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 1,153 participants
Start Date 2023-10-06
Est. Completion 2026-07-30
Phase Phase 3

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06067230

The ClinicalTrials.gov registry entry for NCT06067230 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,153 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (397% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1345 is the first listed.

NCT06067230 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06067230 about?

NCT06067230 is a clinical study titled "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults". The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplan...

What is the current status of trial NCT06067230?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,153 participants. The study started on 2023-10-06. Estimated completion is 2026-07-30.

What conditions does trial NCT06067230 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus.

What interventions are being tested in trial NCT06067230?

The interventions under investigation include: mRNA-1345 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06067230?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06067230 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.